Our data demonstrate that the first three mRNA/LNP-based PanCoVax vaccine candidates (i.e., NSP-2, NSP14, and Nucleocapsid) induced protective CD4+ and CD8+ T-cell-mediated protection against infection with the Delta variant [2]. This evidence concerns the gene CD8A and infection.